FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2951776423> ?p ?o ?g. }

• W2951776423 endingPage "28" @default.
• W2951776423 startingPage "28" @default.
• W2951776423 abstract "Background: B cell precursors acute lymphoblastic leukemia (B-ALL) is the most commonly diagnosed childhood cancer. Major advances in treatments protocols, allowing for the 5-year overall survival rate to reach 90%. However, many children still undergo intensive therapy and will develop relapse after a complete remission. Children with Down syndrome (DS) have a 27-fold increased risk of developing B-ALL and face a dismal prognosis due to treatment-related mortality, and an increased risk of infections and relapse rate. Aims: The goal of the study was to better understand the molecular bases of DS-ALL and develop specific therapies to improve outcomes. Methods: Here, we comprehensively characterized DS-ALL samples, extended our study to other groups of childhood B-ALL carrying gains of chromosome 21 (B-ALL+21) and developed Patient Derived Xenograft (PDX) models suitable for preclinical studies. We performed exome and RNA sequencing to characterize the genetic and transcriptomic landscape of DS-ALL (n = 8), iAMP21-ALL (n = 7), HeH-ALL (n = 14) compared to other pediatric B-ALL (n = 12). Results: Somatic mutations leading to RAS/MAPK pathway activation (affecting the N/KRAS, JAK2, FLT3 and CBL genes) were present in 75% (22/29) of B-ALL +21 samples, confirming recent observations by other group, and strengthening the link between RAS/MAPK pathway activation and +21. To gain insights into the molecular bases of this cooperation, we ectopically expressed the constitutively active mutant KRASG12D in murine bone marrow progenitors. We observed that KRASG12D expression in trisomic progenitors led to an increased number of CFU-preB colonies that presented increased self-renewal capacities compared to wild-type, trisomy 21 or KRASG12D alone. RNA sequencing showed that 261 genes were synergistically deregulated by KRASG12D+Trisomie 21 in murine B cell progenitors, including 24 genes that were transcriptionally deregulated in B-ALL+21 with RAS/MAPK mutations patient samples as compared to healthy B-cell progenitors. Together, tshese results indicated that constitutive RAS activation and +21 functionally cooperates at the cellular and molecular level to impose an altered differentiation of B-cell progenitors. From this cohort, we also developed 18 preclinical PDX models (13 B-ALL+21 and 5 Others) to test the efficacy of inhibitors of the RAS/MAPK pathway. We showed that the most potent compound, Trametinib (GSK1120212), significantly decreased viability of B-ALL+21 blasts presenting a constitutive RAS/MAPK activation in vitro (IC50 = 0,1 ± 0,25 μM compared to 3,95 ± 4,7 μM for B-ALL samples without RAS/MAPK activation). In vivo treatments with Trametinib significantly decreased leukemia burden in the bone marrow and spleen compared to vehicle controls, and increased survival of DS-ALL, iAMP21-ALL and HeH-ALL PDX models. Finally, we assessed the efficacy of Trametinib in combination with conventional chemotherapy agents. We observed that Trametinib synergised with Vincristine in vitro, and delayed leukemia progression in vivo to enhance survival of DS-ALL PDXs. Summary/Conclusion: Altogether, we built a comprehensive cohort of preclinical models of DS-ALL and B-ALL+21, and suggested that inhibiting RAS/MAPK pathway activation in combination with current chemotherapy may represent a promising strategy to improve the outcome of Down syndrome children with B-ALL." @default.
• W2951776423 created "2019-06-27" @default.
• W2951776423 creator A5000781207 @default.
• W2951776423 creator A5001321701 @default.
• W2951776423 creator A5001972982 @default.
• W2951776423 creator A5003014789 @default.
• W2951776423 creator A5008128025 @default.
• W2951776423 creator A5008437464 @default.
• W2951776423 creator A5009884108 @default.
• W2951776423 creator A5011387118 @default.
• W2951776423 creator A5019921020 @default.
• W2951776423 creator A5026484326 @default.
• W2951776423 creator A5033934882 @default.
• W2951776423 creator A5035450613 @default.
• W2951776423 creator A5053450483 @default.
• W2951776423 creator A5056918871 @default.
• W2951776423 creator A5058270449 @default.
• W2951776423 creator A5065478008 @default.
• W2951776423 creator A5071962621 @default.
• W2951776423 creator A5074729243 @default.
• W2951776423 creator A5083826444 @default.
• W2951776423 creator A5084964297 @default.
• W2951776423 creator A5085851050 @default.
• W2951776423 creator A5091173712 @default.
• W2951776423 date "2019-06-01" @default.
• W2951776423 modified "2023-09-23" @default.
• W2951776423 title "PF151 RAS/MAPK ACTIVATION COOPERATES WITH GAIN OF CHROMOSOME 21 IN B CELL LEUKEMIA AND IS AN ATTRACTIVE TARGET TO IMPROVE THE OUTCOME OF DS CHILDREN WITH B-ALL" @default.
• W2951776423 doi "https://doi.org/10.1097/01.hs9.0000558824.04911.df" @default.
• W2951776423 hasPublicationYear "2019" @default.
• W2951776423 type Work @default.
• W2951776423 sameAs 2951776423 @default.
• W2951776423 citedByCount "0" @default.
• W2951776423 crossrefType "journal-article" @default.
• W2951776423 hasAuthorship W2951776423A5000781207 @default.
• W2951776423 hasAuthorship W2951776423A5001321701 @default.
• W2951776423 hasAuthorship W2951776423A5001972982 @default.
• W2951776423 hasAuthorship W2951776423A5003014789 @default.
• W2951776423 hasAuthorship W2951776423A5008128025 @default.
• W2951776423 hasAuthorship W2951776423A5008437464 @default.
• W2951776423 hasAuthorship W2951776423A5009884108 @default.
• W2951776423 hasAuthorship W2951776423A5011387118 @default.
• W2951776423 hasAuthorship W2951776423A5019921020 @default.
• W2951776423 hasAuthorship W2951776423A5026484326 @default.
• W2951776423 hasAuthorship W2951776423A5033934882 @default.
• W2951776423 hasAuthorship W2951776423A5035450613 @default.
• W2951776423 hasAuthorship W2951776423A5053450483 @default.
• W2951776423 hasAuthorship W2951776423A5056918871 @default.
• W2951776423 hasAuthorship W2951776423A5058270449 @default.
• W2951776423 hasAuthorship W2951776423A5065478008 @default.
• W2951776423 hasAuthorship W2951776423A5071962621 @default.
• W2951776423 hasAuthorship W2951776423A5074729243 @default.
• W2951776423 hasAuthorship W2951776423A5083826444 @default.
• W2951776423 hasAuthorship W2951776423A5084964297 @default.
• W2951776423 hasAuthorship W2951776423A5085851050 @default.
• W2951776423 hasAuthorship W2951776423A5091173712 @default.
• W2951776423 hasBestOaLocation W29517764231 @default.
• W2951776423 hasConcept C104317684 @default.
• W2951776423 hasConcept C121608353 @default.
• W2951776423 hasConcept C126322002 @default.
• W2951776423 hasConcept C143998085 @default.
• W2951776423 hasConcept C150194340 @default.
• W2951776423 hasConcept C162317418 @default.
• W2951776423 hasConcept C16671776 @default.
• W2951776423 hasConcept C201750760 @default.
• W2951776423 hasConcept C2778461978 @default.
• W2951776423 hasConcept C2779954681 @default.
• W2951776423 hasConcept C2781187634 @default.
• W2951776423 hasConcept C28328180 @default.
• W2951776423 hasConcept C501734568 @default.
• W2951776423 hasConcept C502942594 @default.
• W2951776423 hasConcept C54355233 @default.
• W2951776423 hasConcept C57074206 @default.
• W2951776423 hasConcept C60644358 @default.
• W2951776423 hasConcept C62478195 @default.
• W2951776423 hasConcept C71924100 @default.
• W2951776423 hasConcept C86803240 @default.
• W2951776423 hasConceptScore W2951776423C104317684 @default.
• W2951776423 hasConceptScore W2951776423C121608353 @default.
• W2951776423 hasConceptScore W2951776423C126322002 @default.
• W2951776423 hasConceptScore W2951776423C143998085 @default.
• W2951776423 hasConceptScore W2951776423C150194340 @default.
• W2951776423 hasConceptScore W2951776423C162317418 @default.
• W2951776423 hasConceptScore W2951776423C16671776 @default.
• W2951776423 hasConceptScore W2951776423C201750760 @default.
• W2951776423 hasConceptScore W2951776423C2778461978 @default.
• W2951776423 hasConceptScore W2951776423C2779954681 @default.
• W2951776423 hasConceptScore W2951776423C2781187634 @default.
• W2951776423 hasConceptScore W2951776423C28328180 @default.
• W2951776423 hasConceptScore W2951776423C501734568 @default.
• W2951776423 hasConceptScore W2951776423C502942594 @default.
• W2951776423 hasConceptScore W2951776423C54355233 @default.
• W2951776423 hasConceptScore W2951776423C57074206 @default.
• W2951776423 hasConceptScore W2951776423C60644358 @default.
• W2951776423 hasConceptScore W2951776423C62478195 @default.
• W2951776423 hasConceptScore W2951776423C71924100 @default.
• W2951776423 hasConceptScore W2951776423C86803240 @default.
• W2951776423 hasIssue "S1" @default.
• W2951776423 hasLocation W29517764231 @default.

• next